StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)

by · The Cerbat Gem

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a report released on Tuesday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Trading Up 5.6 %

Shares of NASDAQ:OPGN opened at $3.40 on Tuesday. The business’s 50 day moving average price is $1.41 and its 200-day moving average price is $1.47. OpGen has a 1 year low of $0.53 and a 1 year high of $8.40.

OpGen Company Profile

(Get Free Report)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Further Reading